Qualigen Enters into Research Agreement for RAS Inhibitor Cancer Drug with University of Louisville (UofL)
Qualigen, Inc., and the University of Louisville (UofL) today announced that Qualigen has entered into a Sponsored Research Agreement (SRA) with UofL for development of several small-molecule RAS Inhibitor drug…